Listen

Gene Therapy Shows Promise For Hemophilia, But Could Be Most Expensive U.S. Drug Ever

Jul 20, 2020
Originally published on July 20, 2020 9:23 am

Jack Grehan, who was born with hemophilia, used to inject himself every couple of days with a protein he needs for his blood to clot. But not anymore.

"It's been absolutely brilliant and life-changing for me," says Grehan, 26, of Billinge in North West England. He received an experimental gene therapy in 2017 that, at least for now, has eliminated his need for regular injections. "I can just go about my day and not have to worry."

Based on experiences like Grehan's, the company that developed the therapy is seeking approval in Europe and the United States to start selling the first gene therapy for hemophilia. That's generating excitement among patients, patient advocates and doctors.

"Not to have to worry about hemophilia any longer — I think it's essentially transformational for many patients," says Dr. John Pasi of the Royal London Hospital and the London School of Medicine and Dentistry. Pasi led the recently published study Grehan took part in.

Jack Grehan, of Billinge, U.K., in North West England, is one recipient of BioMarin's still experimental gene therapy to treat hemophilia. He says his quality of life has improved dramatically since getting an infusion of the drug three years ago.
Jack Grehan

Others are more cautious.

"This is really exciting, but also raises a lot of questions," says Meg Bradbury, director of research at the Hemophilia Federation of America, a patient advocacy group.

One of the biggest questions is the possible cost. BioMarin Pharmaceutical Inc. of San Rafael, Calif., the company that developed the gene therapy, says the treatment could cost as much as $3 million per patient, which would make it the most expensive drug ever approved.

"It's just outrageous," says Peter Bach, who studies drug prices at Memorial Sloan Kettering Cancer Center in New York.

Company officials defend the possible price, however. It currently costs hundreds of thousands of dollars a year to treat each hemophilia patient. The gene therapy would, researchers hope, be a one-time treatment that lasts a lifetime.

"The context is this gigantically expensive disease to treat," says Jeff Ajer, BioMarin's executive vice president and chief commercial officer. "It's likely that our gene therapy would save a lot of money — millions, perhaps many millions."

Hemophilia is a relatively rare condition. Hemophilia A, the most common form of the disease, occurs in 1 of about every 5,000 boys. (Though girls can be born with hemophilia, too, that's much rarer.) People born with the condition are missing a crucial protein that their blood needs to clot. So doing things as simple as walking can cause dangerous bleeding in their joints that eventually can be crippling.

"It was quite difficult, because I was always getting these bleeds in the ankles," Grehan says. "So walking around was becoming more and more troublesome."

Grehan has a severe form of hemophilia A, which causes a deficiency in a clotting protein called factor VIII.

"It's the microbleeds that just sort of wear your down — not even physically but mentally," Grehan says.

And Grehan knew that propensity to bleed could cause even more serious, possibly fatal, complications if the hemorrhage every happened in his brain or other parts of his body.

"Internally, there could have been a lot worse situations," Grehan says. "I consider myself quite lucky in that respect."

Before anything like that happened to Grehan, he learned that doctors were testing the gene therapy.

"When I first heard about the trial I thought it was unbelievable that we were in this situation — that this even existed," Grehan says.

So he volunteered three years ago to let doctors infuse trillions of neutralized viruses that had been genetically engineered to carry the healthy gene he needed into his liver.

Within a couple of weeks, Grehan could stop injecting himself with the clotting protein that he had previously needed.

In fact, the treatment dramatically cut bleeding in all 13 of the patients who got the effective dose of gene therapy determined by the study Grehan was in.

"I think it's amazing data actually," Pasi says. "It's been the Holy Grail for years to be able to treat hemophilia with a gene therapy treatment. And maybe we're beginning to see that that wasn't a pipe dream — that this is a realistic option."

It's the latest promising development for gene therapy, which has finally started producing effective treatments for a variety of diseases after decades of setbacks.

Several other experimental forms of gene therapy are also showing promise for hemophilia, including another type of the condition, known as hemophilia B.

So far, nearly 150 patients have been treated with BioMarin's gene therapy as part of a larger study, and the results continue to be encouraging, according to the company. Some patients having been followed for as long as four years.

"For a good fraction of these people, they don't have to even think about having hemophilia anymore," says Henry Fuchs, president of research and development at BioMarin.

The Food and Drug Administration has designated the treatment a "breakthrough" therapy and accepted the company's application to give the gene therapy priority status for evaluation, representatives of BioMarin say. That makes it the first gene therapy for hemophilia the agency has agreed to consider.

According to the company, the FDA has signaled it will make its decision by Aug. 21 about whether to approve the treatment for sale.

Longer studies will be need to determine if the treatment is, in fact, a one-time, therapy for lifelong effect, experts say.

"It seems to be working very well, but we are only at three years," says Dr. W. Keith Hoots, director of the division of blood diseases and resources at the National Heart, Lung and Blood Institute. "We need to know for sure whether it will extend for their entire life. And only time will tell for that."

Nevertheless, Bach agrees the treatment appears very promising. Still, he questions the price tag, which would be just the latest in what appears to be an ongoing rise in the cost of the new wave of genetic therapies.

"The clinical breakthrough is prodigious. We should be thrilled by it," Bach says.

"But the greatest innovation by the pharmaceutical industry is not the biologic breakthroughs they're making," he says. "It's their ability to extract money from society that we could put into other things — like better benefits in Medicare, lower out-of-pocket costs for poor people, dental coverage and things like that."

The prices of the drugs already used to treat hemophilia are inflated, Bach argues.

Bradbury, from the Hemophilia Federation of America, agrees cost is a concern.

"We need to make sure all those who are eligible would have access to it," Bradbury says.

Ajer says the company has already been negotiating with insurance companies and government programs to cover the costs.

"Our work is not done here, but my expectation is that most of the patients who need access to therapy would be able to get it, in not a terribly long time, through their insurance system," Ajer says.

As someone who has had to deal with hemophilia all his life, Grehan thinks the price is reasonable.

"I think $3 million for this is very cheap — because it is life-changing," Grehan says. "And if you're going to spend hundreds of thousands of dollars a year over a lifetime, that seems worth it to me."

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

There's new hope for people who have the blood-clotting disorder hemophilia. Gene therapy seems to be working for patients, but the cost of it is raising some tough questions. Here's NPR health correspondent Rob Stein.

ROB STEIN, BYLINE: Jack Grehan was born with hemophilia, so doing something as simple as just walking down the street could cause big problems for his ankles.

JACK GREHAN: I was always get in these bleeds in the ankles, so walking around was becoming more and more troublesome.

STEIN: Because people with hemophilia are missing a crucial protein that blood needs to clot, so just walking can cause dangerous bleeding in their joints that eventually can be crippling.

GREHAN: It's the microbleeds that just sort of way you down - not even physically, but mentally - you know, having to just stop and rest and ice an ankle that you feel is bleeding, just having to pause your life sort of every day.

STEIN: And Grehan, who's 26 and lives in Billinge, England, knew that hemophilia can cause even more serious, even possibly fatal, complications if the bleeding happens in the brain or other parts of the body.

GREHAN: Internally, there could have been a lot worse situations. But, you know, I consider myself quite lucky in that respect.

STEIN: Because before anything terrible happened to Grehan, he heard that doctors were testing a new way to treat hemophilia - a new kind of gene therapy that would actually fix the genetic defect that causes hemophilia.

GREHAN: When I first heard about the trial, I thought it was unbelievable that we're in this situation, that this even existed.

STEIN: So he jumped at the chance to volunteer. Doctors infused trillions of harmless viruses that had been genetically engineered to carry a healthy gene into his liver. And it worked. Within a couple of weeks, he could stop injecting himself with the clotting protein he had needed every couple of days his entire life.

GREHAN: It's been absolutely brilliant and life-changing for me. I can just go about my day and not have to worry.

STEIN: And gene therapy appears to be working for other people with hemophilia, too.

JOHN PASI: Not to have to worry about hemophilia any longer, I think it's, essentially, transformational for many patients.

STEIN: John Pasi of the Royal London Hospital ran the study Grehan was in. He says the treatment dramatically cut bleeding in all 13 patients who got the same gene therapy Grehan got. They all had the most severe form of the most common form of hemophilia.

PASI: I think it's amazing data, actually. It's been the Holy Grail for years to be able to treat hemophilia with a gene therapy treatment. And maybe we're beginning to see that that wasn't a pipe dream and that this is a realistic option.

STEIN: It's the latest promising development for gene therapy, which has finally started producing effective treatments for a variety of diseases after decades of setbacks. In fact, the company developing the gene therapy Grehan got says nearly 150 patients have now been treated, and the results are so encouraging that the company's asking for approval in Europe and the United States.

JEFF AJER: It is such a major advance.

STEIN: Jeff Ajer is an executive vice president at the California company called BioMarin.

AJER: When I was, you know, a young man working in this industry, we talked about gene therapies. It felt like science fiction at the time. And to be standing here all these years later, to have these huge benefits to patients' lives, is very exciting.

STEIN: Now, there are lots of questions about this. One big one is - will the gene therapy keep working or will it eventually wear off? And if it gets approved, BioMarin says this gene therapy for hemophilia won't come cheap. The company says it could cost as much as $3 million per patient, and that would make it the most expensive drug ever.

PETER BACH: It's just outrageous.

STEIN: That's Peter Bach. He studies drug prices at Memorial Sloan Kettering in New York. He says the price tag on each of these new gene therapies just keeps getting higher and higher.

BACH: A clinical breakthrough is prodigious. We should be thrilled by it. But the greatest innovation in the pharmaceutical industry is not the biologic breakthroughs they're making; it's their ability to extract money from society that we could put into other things, like better benefits in Medicare, lower out-of-pocket costs for poor people, dental coverage and things like that.

STEIN: Drug company officials defend the price. It can cost hundreds of thousands of dollars a year to treat hemophilia and millions over a lifetime. This will hopefully be a one-time treatment that lasts a lifetime. So, Ajer says, it could actually save tens of millions of dollars in the long run.

AJER: It's likely that our gene therapy would save a lot of money - millions, perhaps many millions.

STEIN: Ajer says the company is working to make sure the treatment would be available to any patients who need it. The company is already negotiating with insurance companies and government programs to pay for it. For his part, Grehan also thinks the price is reasonable.

GREHAN: I think $3 million for this is very cheap because it is life-changing. And if you're going to spend hundreds of thousands of dollars a year over a lifetime, that seems worth it to me.

STEIN: Other gene therapies are also showing promise for hemophilia, and the Food and Drug Administration will decide whether to approve this first one by the end of the summer.

Rob Stein, NPR News.

(SOUNDBITE OF MUSIC) Transcript provided by NPR, Copyright NPR.